Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | JAK1 | P23458 | 1/20 | 0.58 |
| ▸ | NOS1 | P29475 | 4/20 | 0.53 |
| ▸ | AXL | P30530 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | DHPS | P49366 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16701653 | 0.81 | JAK2 (0.58) | JAK2JAK1NOS1AXLNPC1 | |
| SCHEMBL16703680 | 0.81 | JAK2 (0.58) | JAK2JAK1NOS1AXLNPC1 | |
| SCHEMBL8306066 | 0.81 | JAK2 (0.68) | JAK2JAK1NOS1AXLNPC1 | |
| SCHEMBL18193501 | 0.81 | JAK2 (0.58) | JAK2JAK1NOS1AXLNPC1 | |
| SCHEMBL1853888 | 0.78 | NPC1 (0.62) | JAK2JAK1NPC1HTTRAB9A | |
| SCHEMBL30964006 | 0.78 | NPC1 (0.62) | JAK2JAK1NPC1HTTRAB9A | |
| SCHEMBL11735958 | 0.78 | ALDH1A1 (0.61) | JAK2JAK1NOS1AXLNPC1 | |
| SCHEMBL7572136 | 0.78 | JAK2 (0.55) | JAK2JAK1NOS1AXLNPC1 | |
| SCHEMBL23593790 | 0.77 | JAK2 (0.54) | JAK2JAK1NOS1AXLNPC1 | |
| SCHEMBL21964331 | 0.77 | JAK2 (0.58) | JAK2JAK1NOS1AXLNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-3558969-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-18 | — | — | EP | disclosed |
| US-12077521-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-03 | — | — | US | disclosed |
| US-20220315557-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. | 2022-10-06 | — | — | US | disclosed |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2022-08-11 | — | — | US | disclosed |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2022-04-05 | — | — | US | disclosed |
| US-10954214-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-23 | — | — | US | disclosed |
| US-10954214-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-23 | — | — | US | disclosed |
| EP-3558969-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2019-10-30 | — | — | EP | disclosed |
| CN-110214136-A | Pyrazole derivatives as MALT1 inhibitor | 詹森药业有限公司 | 2019-09-06 | — | — | CN | disclosed |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2019-04-18 | — | — | US | disclosed |
| WO-2018119036-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119036-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | disclosed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | disclosed |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | JAK2 2038/4885JAK1 4196/4885NOS1 2896/4885 |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | JAK2 2038/4885JAK1 4196/4885NOS1 2896/4885 |
| US-20220315557-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | MALT1, PPP3R1, SQSTM1 | JAK2 3714/4885JAK1 2360/4885NOS1 1494/4885 |
| US-10954214-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | JAK2 3714/4885JAK1 2360/4885NOS1 1494/4885 |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | JAK2 2038/4885JAK1 4196/4885NOS1 2896/4885 |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | JAK2 2038/4885JAK1 4196/4885NOS1 2896/4885 |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | JAK2 2038/4885JAK1 4196/4885NOS1 2896/4885 |
| US-12077521-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | JAK2 3714/4885JAK1 2360/4885NOS1 1494/4885 |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | MALT1, PPP3R1, SQSTM1 | JAK2 3714/4885JAK1 2360/4885NOS1 1494/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | JAK2 146/4885JAK1 1669/4885NOS1 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.